NAD+ decline and the case for multi-pathway supplementation
A review of what happens to nicotinamide adenine dinucleotide as we age — and how the AgeleX formulation was designed around the published evidence.
NAD+ is a coenzyme required for cellular energy production and DNA repair. Tissue concentrations decline markedly with age — analyses of human skin and muscle place the loss at up to 65% between ages 30 and 70.1 Oral nicotinamide riboside (NR) has been shown in randomized controlled trials to raise whole-blood NAD+ in a dose-dependent manner.2 This brief summarizes the decline curve, the NR pathway, and the rationale for pairing NR with eleven supporting compounds rather than supplementing it alone.
The molecule behind every calorie you burn
Nicotinamide adenine dinucleotide (NAD+) shuttles electrons through the mitochondrial chain that converts food into ATP — the energy currency your 37.2 trillion cells actually spend. Beyond metabolism, NAD+ is the required substrate for sirtuins and PARP enzymes, the proteins that maintain and repair DNA.
When NAD+ is abundant, cells produce energy and run repair simultaneously. When it is scarce, the two systems compete — and repair loses.
Half gone by fifty
Massudi and colleagues measured NAD+ in human tissue across age groups and found a strong negative correlation with age, alongside rising markers of oxidative DNA damage.1 The practical reading: by the fifth decade, most people run on roughly half the NAD+ they had at thirty.
The decline is not linear willpower loss — it is measurable chemistry: afternoon energy dips, slower recovery, and duller skin all sit downstream of the same depleted coenzyme.
One enzymatic step from precursor to coenzyme
Cells cannot absorb NAD+ directly — it must be built from a precursor. Among the candidates, nicotinamide riboside (NR) carries the largest body of published human research. NR enters cells through dedicated transporters and converts to NAD+ in a single kinase step:
Scroll sideways to explore the pathway →
In the largest published NR trial to date, two weeks of daily oral NR raised whole-blood NAD+ by 51% at 300 mg and 142% at 1,000 mg — a clear dose-response, with a safety profile comparable to placebo.2
AgeleX supplies 500 mg of NR per serving — inside the range where the trial showed meaningful elevation. These results describe the studied ingredient; they are not a claim about the finished AgeleX product. Reported adverse-event rates in the trial were comparable to placebo at every dose.2
Aging doesn't happen on one front
Raising NAD+ addresses the supply side of cellular energy. But the systems that use NAD+ — mitochondria, neurons, skin, antioxidant defenses — have needs of their own. The AgeleX formulation pairs NR with eleven compounds, each selected from published research on one of four fronts:
An honest note on limitations
NAD+ research in humans is young. Trials show NR reliably raises blood NAD+; they do not yet prove downstream outcomes like longer life or reversed aging, and results describe individual ingredients rather than this finished product. AgeleX is formulated on the published dose ranges — and we will update this page as the evidence base grows.
- Massudi H, Grant R, Braidy N, et al. Age-associated changes in oxidative stress and NAD+ metabolism in human tissue. PLoS ONE. 2012;7(7):e42357.
- Conze D, Brenner C, Kruger CL. Safety and metabolism of long-term administration of NIAGEN (nicotinamide riboside chloride) in a randomized, double-blind, placebo-controlled clinical trial of healthy overweight adults. Sci Rep. 2019;9:9772 (n=140).
- Bogan KL, Brenner C. Nicotinic acid, nicotinamide, and nicotinamide riboside: a molecular evaluation of NAD+ precursor vitamins in human nutrition. Annu Rev Nutr. 2008;28:115-130.
† These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Cited results describe studied ingredients, not the AgeleX product.